Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Status: Enrolling
Updated:  8/22/2011
Children's Hospital and Research Center Oakland
2098
mi
from 43215
Oakland, CA
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Status: Enrolling
Updated: 8/22/2011
Children's Hospital and Research Center Oakland
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD
Intravenous Iron Sucrose Versus Oral Ferrous Sulfate in Treating Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease
Status: Enrolling
Updated:  9/21/2011
Children's Hospital of Michigan
164
mi
from 43215
Detroit, MI
IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD
Intravenous Iron Sucrose Versus Oral Ferrous Sulfate in Treating Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease
Status: Enrolling
Updated: 9/21/2011
Children's Hospital of Michigan
164
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Treatment of Sickle Cell Vaso-Occlusive Crises With High-Dose Intravenous Gammaglobulin
Status: Enrolling
Updated:  9/26/2011
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Treatment of Sickle Cell Vaso-Occlusive Crises With High-Dose Intravenous Gammaglobulin
Status: Enrolling
Updated: 9/26/2011
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Treatment of Sickle Cell Vaso-Occlusive Crises With High-Dose Intravenous Gammaglobulin
Status: Enrolling
Updated:  9/26/2011
Mount Sinai School of Medicine
480
mi
from 43215
New York, NY
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Treatment of Sickle Cell Vaso-Occlusive Crises With High-Dose Intravenous Gammaglobulin
Status: Enrolling
Updated: 9/26/2011
Mount Sinai School of Medicine
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases
Status: Enrolling
Updated:  10/18/2011
Columbia University Medical Center
477
mi
from 43215
New York, NY
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases
Status: Enrolling
Updated: 10/18/2011
Columbia University Medical Center
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
Socialization of Adult Men With Congenital Hemophilia A or B
Socialization of Adult Men With Congenital Hemophilia A or B: A Study to Examine Socialization Measures, the Role of Spouse/Significant Other and Health Related Quality of Life
Status: Enrolling
Updated:  1/13/2012
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Socialization of Adult Men With Congenital Hemophilia A or B
Socialization of Adult Men With Congenital Hemophilia A or B: A Study to Examine Socialization Measures, the Role of Spouse/Significant Other and Health Related Quality of Life
Status: Enrolling
Updated: 1/13/2012
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Validation of the Sickle Cell Disease Pain Burden Interview
Status: Enrolling
Updated:  2/8/2012
Connecticut Children's Medical Center
553
mi
from 43215
Hartford, CT
Validation of the Sickle Cell Disease Pain Burden Interview
Status: Enrolling
Updated: 2/8/2012
Connecticut Children's Medical Center
553
mi
from 43215
Hartford, CT
Click here to add this to my saved trials
Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain
Psychometric Evaluation of the Inpatient Pediatric Physical Activity Questionnaire (IPPAQ) in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain
Status: Enrolling
Updated:  2/8/2012
Connecticut Children's Medical Center
553
mi
from 43215
Hartford, CT
Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain
Psychometric Evaluation of the Inpatient Pediatric Physical Activity Questionnaire (IPPAQ) in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain
Status: Enrolling
Updated: 2/8/2012
Connecticut Children's Medical Center
553
mi
from 43215
Hartford, CT
Click here to add this to my saved trials
Identification of Early Predictors of Fetomaternal Hemorrhage
Identification of Early Predictors of Fetomaternal Hemorrhage And Development Of An Automated Screening Strategy For At-Risk Pregnancies
Status: Enrolling
Updated:  2/16/2012
Mount Sinai School of Medicine
480
mi
from 43215
New York, NY
Identification of Early Predictors of Fetomaternal Hemorrhage
Identification of Early Predictors of Fetomaternal Hemorrhage And Development Of An Automated Screening Strategy For At-Risk Pregnancies
Status: Enrolling
Updated: 2/16/2012
Mount Sinai School of Medicine
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Status: Enrolling
Updated:  2/21/2012
Virginia Commonwealth University Health System
344
mi
from 43215
Richmond, VA
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Status: Enrolling
Updated: 2/21/2012
Virginia Commonwealth University Health System
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Status: Enrolling
Updated:  3/8/2012
Baylor College of Medicine, Ben Taub General Hospital
995
mi
from 43215
Houston, TX
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Status: Enrolling
Updated: 3/8/2012
Baylor College of Medicine, Ben Taub General Hospital
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Study of ACE-536 in Healthy Postmenopausal Women
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-536 in Healthy Postmenopausal Women
Status: Enrolling
Updated:  3/14/2012
Acceleron Investigative Site
1656
mi
from 43215
Tempe, AZ
Study of ACE-536 in Healthy Postmenopausal Women
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-536 in Healthy Postmenopausal Women
Status: Enrolling
Updated: 3/14/2012
Acceleron Investigative Site
1656
mi
from 43215
Tempe, AZ
Click here to add this to my saved trials
Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn
Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn
Status: Enrolling
Updated:  3/21/2012
Highland Hospital
355
mi
from 43215
Rochester, NY
Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn
Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn
Status: Enrolling
Updated: 3/21/2012
Highland Hospital
355
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Prevention of Iron Deficiency in Breastfed Infants
Prevention of Iron Deficiency in Breastfed Infants
Status: Enrolling
Updated:  4/26/2012
University of Iowa
461
mi
from 43215
Iowa City, IA
Prevention of Iron Deficiency in Breastfed Infants
Prevention of Iron Deficiency in Breastfed Infants
Status: Enrolling
Updated: 4/26/2012
University of Iowa
461
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Evaluate the Change in Iron, Vitamin D, and C-Reactive Protein Level (CRP) in a 12 to 24 Week Period
Observational Study to Evaluate Changes in Iron, Vit-D, and CRP During a Twelve to Twenty-Four Week Supervised Triathlon Training Program
Status: Enrolling
Updated:  5/31/2012
Avera Sports Institute
747
mi
from 43215
Sioux Falls, SD
Evaluate the Change in Iron, Vitamin D, and C-Reactive Protein Level (CRP) in a 12 to 24 Week Period
Observational Study to Evaluate Changes in Iron, Vit-D, and CRP During a Twelve to Twenty-Four Week Supervised Triathlon Training Program
Status: Enrolling
Updated: 5/31/2012
Avera Sports Institute
747
mi
from 43215
Sioux Falls, SD
Click here to add this to my saved trials
Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease
A Pilot Study of Treatment of Adults With Sickle Cell Disease Associated Pulmonary Hypertension Based on Hemodynamic Stratification: Safety and Tolerability Study of Imatinib and Carvedilol
Status: Enrolling
Updated:  6/28/2012
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease
A Pilot Study of Treatment of Adults With Sickle Cell Disease Associated Pulmonary Hypertension Based on Hemodynamic Stratification: Safety and Tolerability Study of Imatinib and Carvedilol
Status: Enrolling
Updated: 6/28/2012
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
Status: Enrolling
Updated:  7/3/2012
Univ of North Carolina
353
mi
from 43215
Chapel Hill, NC
Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
Status: Enrolling
Updated: 7/3/2012
Univ of North Carolina
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).
Status: Enrolling
Updated:  7/11/2012
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).
Status: Enrolling
Updated: 7/11/2012
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).
Status: Enrolling
Updated:  7/11/2012
Gabrail Cancer Center
103
mi
from 43215
Canton, OH
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).
Status: Enrolling
Updated: 7/11/2012
Gabrail Cancer Center
103
mi
from 43215
Canton, OH
Click here to add this to my saved trials
Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
Epoetin Alfa in the Treatment of Post-Transplant Anemia: A Randomized Controlled Trial
Status: Enrolling
Updated:  7/20/2012
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
Epoetin Alfa in the Treatment of Post-Transplant Anemia: A Randomized Controlled Trial
Status: Enrolling
Updated: 7/20/2012
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Study of Severe Hemophilia A Patients Who Have Only Received a Single Recombinant FVIII Therapeutic for the Purpose of Identifying the Pharmacogenetic Determinants of Tolerance and Immunogenicity
Status: Enrolling
Updated:  7/25/2012
Children's Hospital of Michigan
164
mi
from 43215
Detroit, MI
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Study of Severe Hemophilia A Patients Who Have Only Received a Single Recombinant FVIII Therapeutic for the Purpose of Identifying the Pharmacogenetic Determinants of Tolerance and Immunogenicity
Status: Enrolling
Updated: 7/25/2012
Children's Hospital of Michigan
164
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  8/5/2012
Duke University Medical Center Pediatric Blood and Marrow Transplant Program
351
mi
from 43215
Durham, NC
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 8/5/2012
Duke University Medical Center Pediatric Blood and Marrow Transplant Program
351
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Status: Enrolling
Updated:  8/21/2012
Clinical Research Facility
2091
mi
from 43215
Santa Clara, CA
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Status: Enrolling
Updated: 8/21/2012
Clinical Research Facility
2091
mi
from 43215
Santa Clara, CA
Click here to add this to my saved trials
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Status: Enrolling
Updated:  8/21/2012
Clinical Research Facility
164
mi
from 43215
Ann Arbor, MI
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Status: Enrolling
Updated: 8/21/2012
Clinical Research Facility
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
Status: Enrolling
Updated:  8/23/2012
GSK Investigational Site
322
mi
from 43215
Bethesda, MD
Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
Status: Enrolling
Updated: 8/23/2012
GSK Investigational Site
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated:  8/29/2012
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated: 8/29/2012
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated:  8/29/2012
James Cancer Hospital
1
mi
from 43215
Columbus, OH
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Status: Enrolling
Updated: 8/29/2012
James Cancer Hospital
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I
RESCUED: Phase I: Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency
Status: Enrolling
Updated:  10/2/2012
Mount Sinai School of Medicine
480
mi
from 43215
New York, NY
Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I
RESCUED: Phase I: Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency
Status: Enrolling
Updated: 10/2/2012
Mount Sinai School of Medicine
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Status: Enrolling
Updated:  10/24/2012
Johns Hopkins Hospital
345
mi
from 43215
Baltimore, MD
Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Status: Enrolling
Updated: 10/24/2012
Johns Hopkins Hospital
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
1973
mi
from 43215
Los Angeles, CA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
1973
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
328
mi
from 43215
Washington,
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
328
mi
from 43215
Washington,
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
276
mi
from 43215
Chicago, IL
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
276
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
798
mi
from 43215
Alexandria, LA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
798
mi
from 43215
Alexandria, LA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
643
mi
from 43215
Boston, MA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
353
mi
from 43215
Chapel Hill, NC
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
89
mi
from 43215
Cincinnati, OH
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
89
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated:  12/11/2012
Howard University Hospital
328
mi
from 43215
Washington,
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Howard University Hospital
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated:  12/11/2012
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated:  12/11/2012
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated:  12/11/2012
Brigham and Women's Hosp
643
mi
from 43215
Boston, MA
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Brigham and Women's Hosp
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated:  12/11/2012
Children's Hospital - Boston
640
mi
from 43215
Boston, MA
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Children's Hospital - Boston
640
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated:  12/11/2012
Washington University
397
mi
from 43215
St. Louis, MO
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
Washington University
397
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated:  12/11/2012
The Blood Center of Wisconsin
330
mi
from 43215
Milwaukee, WI
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 12/11/2012
The Blood Center of Wisconsin
330
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
Phase I Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated:  1/14/2013
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
Phase I Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
Status: Enrolling
Updated: 1/14/2013
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Randomized Double Blind Placebo Controlled Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose LMWH Versus Placebo
Status: Enrolling
Updated:  1/17/2013
Duke University
352
mi
from 43215
Durham, NC
Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Randomized Double Blind Placebo Controlled Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose LMWH Versus Placebo
Status: Enrolling
Updated: 1/17/2013
Duke University
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Iron Depletion and Replacement in Blood Donors
Iron Depletion and Replacement in Blood Donors
Status: Enrolling
Updated:  1/17/2013
Memorial Blood Centers
617
mi
from 43215
St. Paul, MN
Iron Depletion and Replacement in Blood Donors
Iron Depletion and Replacement in Blood Donors
Status: Enrolling
Updated: 1/17/2013
Memorial Blood Centers
617
mi
from 43215
St. Paul, MN
Click here to add this to my saved trials
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated:  1/25/2013
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated:  1/25/2013
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Status: Enrolling
Updated: 1/25/2013
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials